Accueil>>Signaling Pathways>> Microbiology & Virology>> Arenavirus>>Retro-2

Retro-2 (Synonyms: RN 1-001)

Catalog No.GC18485

Retro-2 (RN 1-001) est un dihydroquinazolinone (DHQZ) inhibiteur du trafic rétrograde.

Products are for research use only. Not for human use. We do not sell to patients.

Retro-2 Chemical Structure

Cas No.: 1429192-00-6

Taille Prix Stock Qté
10mM 1 mL in DMSO
84,00 $US
En stock
5mg
77,00 $US
En stock
10mg
126,00 $US
En stock
50mg
378,00 $US
En stock
100mg
612,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
Retro-2 is a selective inhibitor of retrograde protein trafficking mediated by syntaxin-5 at the interface between the endosome and trans-Golgi network, with no discernable effects on other intracellular trafficking pathways. Retro-2 inhibits ebolavirus infection with an EC50 value of 12.2 uM and reduces ricin-induced toxicity by 2.7-fold when used at a concentration of 20 uM in HeLa cells. Retro-2 also blocks JC polyomavirus, BK polyomavirus, and SV40 infectivity in Vero green monkey kidney epithelial cells in vitro (EC50s = 28.4, 61.2, and 58.6 uM, respectively). In mouse models, Retro-2 improves survival and reduces symptoms following infection with Shiga toxin-producing E. coli when administered at a dose of 100 mg/kg and protects against ricin challenge when administered prophylactically at a dose of 2 mg/kg.

Avis

Review for Retro-2

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Retro-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.